Cargando…

Reflectance Confocal Microscopy Follow-up of Multifocal Superficial Basal Cell Carcinomas Treated With Imiquimod 5% Cream

INTRODUCTION: Patients with multifocal superficial basal cell carcinomas (sBCC) require a non-invasive treatment and follow-up with a non-invasive technique. Imiquimod 5% cream is a new non-invasive therapy for BCC. Reflectance confocal microscopy (RCM) is a non-invasive, real-time imaging technique...

Descripción completa

Detalles Bibliográficos
Autores principales: Zou, Yunmin, Zhu, Xiaohong, Xia, Rushan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681225/
https://www.ncbi.nlm.nih.gov/pubmed/36534551
http://dx.doi.org/10.5826/dpc.1204a207
_version_ 1784834572900368384
author Zou, Yunmin
Zhu, Xiaohong
Xia, Rushan
author_facet Zou, Yunmin
Zhu, Xiaohong
Xia, Rushan
author_sort Zou, Yunmin
collection PubMed
description INTRODUCTION: Patients with multifocal superficial basal cell carcinomas (sBCC) require a non-invasive treatment and follow-up with a non-invasive technique. Imiquimod 5% cream is a new non-invasive therapy for BCC. Reflectance confocal microscopy (RCM) is a non-invasive, real-time imaging technique. OBJECTIVES: To evaluate and describe the feasibility and efficacy of imiquimod 5% cream for the treatment of multifocal sBCC using RCM. METHODS: The efficacy of imiquimod 5% cream for the treatment of multifocal sBCC was evaluated, as well as the potential of RCM for assessing therapeutic effects. We reported four patients with 34 sBCC lesions were treated with imiquimod 5% cream. RCM was performed in the baseline and at 12 weeks, 24 weeks and 52 weeks after starting treatment. RESULTS: Of 34 lesions treated with imiquimod 5%, 32 responded to the treatment and showed complete clinical clearing. Two subclinical BCC lesions were identified by RCM. The complete tumor clearance rate was 88.2%, and the efficiency rate was 97.1%. No lesion recurred at 24-month follow-up. RCM identified previously described confocal features of BCC and was more sensitive than clinical examination. Local skin reactions were relieved after expectant treatment. CONCLUSIONS: Imiquimod 5% cream may be useful for the treatment of multifocal sBCC, and its side effects are easy to manage. RCM can be used for non-invasive monitoring of treatment response and improved the tumor clearance rate.
format Online
Article
Text
id pubmed-9681225
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Mattioli 1885
record_format MEDLINE/PubMed
spelling pubmed-96812252022-12-02 Reflectance Confocal Microscopy Follow-up of Multifocal Superficial Basal Cell Carcinomas Treated With Imiquimod 5% Cream Zou, Yunmin Zhu, Xiaohong Xia, Rushan Dermatol Pract Concept Original Article INTRODUCTION: Patients with multifocal superficial basal cell carcinomas (sBCC) require a non-invasive treatment and follow-up with a non-invasive technique. Imiquimod 5% cream is a new non-invasive therapy for BCC. Reflectance confocal microscopy (RCM) is a non-invasive, real-time imaging technique. OBJECTIVES: To evaluate and describe the feasibility and efficacy of imiquimod 5% cream for the treatment of multifocal sBCC using RCM. METHODS: The efficacy of imiquimod 5% cream for the treatment of multifocal sBCC was evaluated, as well as the potential of RCM for assessing therapeutic effects. We reported four patients with 34 sBCC lesions were treated with imiquimod 5% cream. RCM was performed in the baseline and at 12 weeks, 24 weeks and 52 weeks after starting treatment. RESULTS: Of 34 lesions treated with imiquimod 5%, 32 responded to the treatment and showed complete clinical clearing. Two subclinical BCC lesions were identified by RCM. The complete tumor clearance rate was 88.2%, and the efficiency rate was 97.1%. No lesion recurred at 24-month follow-up. RCM identified previously described confocal features of BCC and was more sensitive than clinical examination. Local skin reactions were relieved after expectant treatment. CONCLUSIONS: Imiquimod 5% cream may be useful for the treatment of multifocal sBCC, and its side effects are easy to manage. RCM can be used for non-invasive monitoring of treatment response and improved the tumor clearance rate. Mattioli 1885 2022-10-01 /pmc/articles/PMC9681225/ /pubmed/36534551 http://dx.doi.org/10.5826/dpc.1204a207 Text en ©2022 Zou et al. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (BY-NC-4.0), https://creativecommons.org/licenses/by-nc/4.0/, which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original authors and source are credited.
spellingShingle Original Article
Zou, Yunmin
Zhu, Xiaohong
Xia, Rushan
Reflectance Confocal Microscopy Follow-up of Multifocal Superficial Basal Cell Carcinomas Treated With Imiquimod 5% Cream
title Reflectance Confocal Microscopy Follow-up of Multifocal Superficial Basal Cell Carcinomas Treated With Imiquimod 5% Cream
title_full Reflectance Confocal Microscopy Follow-up of Multifocal Superficial Basal Cell Carcinomas Treated With Imiquimod 5% Cream
title_fullStr Reflectance Confocal Microscopy Follow-up of Multifocal Superficial Basal Cell Carcinomas Treated With Imiquimod 5% Cream
title_full_unstemmed Reflectance Confocal Microscopy Follow-up of Multifocal Superficial Basal Cell Carcinomas Treated With Imiquimod 5% Cream
title_short Reflectance Confocal Microscopy Follow-up of Multifocal Superficial Basal Cell Carcinomas Treated With Imiquimod 5% Cream
title_sort reflectance confocal microscopy follow-up of multifocal superficial basal cell carcinomas treated with imiquimod 5% cream
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681225/
https://www.ncbi.nlm.nih.gov/pubmed/36534551
http://dx.doi.org/10.5826/dpc.1204a207
work_keys_str_mv AT zouyunmin reflectanceconfocalmicroscopyfollowupofmultifocalsuperficialbasalcellcarcinomastreatedwithimiquimod5cream
AT zhuxiaohong reflectanceconfocalmicroscopyfollowupofmultifocalsuperficialbasalcellcarcinomastreatedwithimiquimod5cream
AT xiarushan reflectanceconfocalmicroscopyfollowupofmultifocalsuperficialbasalcellcarcinomastreatedwithimiquimod5cream